A Pravastatin Dose-escalation Study in Systemic Lupus Erythematosus

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2007 Apr 4

PMID 17404733

Citations 20

Authors

Karen H Costenbader

Matthew H Liang

Lori B Chibnik

Juliet Aizer

Hannah Kwon

Victoria Gall

Elizabeth W Karlson

Affiliations

Soon will be listed here.

Abstract

Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (+/-12.1%) and LDL by 24% (+/-17%), compared with 1.8% (+/-7.5%) and 2.6% (+/-8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.

Citing Articles

CD38 in SLE CD4 T cells promotes Ca flux and suppresses interleukin-2 production by enhancing the expression of GM2 on the surface membrane.

Katsuyama E, Humbel M, Suarez-Fueyo A, Satyam A, Yoshida N, Kyttaris V Nat Commun. 2024; 15(1):8304.

PMID: 39333474 PMC: 11436706. DOI: 10.1038/s41467-024-52617-7.

Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study.

Hurst C, Soto M, Vina E, Rodgers K Am J Med. 2022; 136(3):284-293.e4.

PMID: 36495935 PMC: 9957968. DOI: 10.1016/j.amjmed.2022.11.016.

Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.

Keyes E, Grinnell M, Jacoby D, Vazquez T, Diaz D, Werth V Int J Womens Dermatol. 2022; 7(5Part A):560-575.

PMID: 35024413 PMC: 8721062. DOI: 10.1016/j.ijwd.2021.08.015.

Management of cardiovascular disease in patients with systemic lupus erythematosus.

Piranavan P, Perl A Expert Opin Pharmacother. 2020; 21(13):1617-1628.

PMID: 32511034 PMC: 7451028. DOI: 10.1080/14656566.2020.1770227.

Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population.

Chen S, Barbhaiya M, Fischer M, Guan H, Lin T, Feldman C Arthritis Care Res (Hoboken). 2018; 71(1):104-115.

PMID: 29648687 PMC: 6185821. DOI: 10.1002/acr.23574.

References

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

Petri M, Perez-Gutthann S, Spence D, Hochberg M . Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992; 93(5):513-9. DOI: 10.1016/0002-9343(92)90578-y. View

Urowitz M, Gladman D . How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford). 2000; 39(3):238-44. DOI: 10.1093/rheumatology/39.3.238. View

Lieberman E, Gerhard M, Uehata A, Selwyn A, Ganz P, Yeung A . Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol. 1996; 78(11):1210-4. DOI: 10.1016/s0002-9149(96)00597-8. View

Knopp R . Drug treatment of lipid disorders. N Engl J Med. 1999; 341(7):498-511. DOI: 10.1056/NEJM199908123410707. View

Lennernas H, Fager G . Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997; 32(5):403-25. DOI: 10.2165/00003088-199732050-00005. View

McCarey D, McInnes I, Madhok R, Hampson R, Scherbakov O, Ford I . Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004; 363(9426):2015-21. DOI: 10.1016/S0140-6736(04)16449-0. View

Asanuma Y, Oeser A, Shintani A, Turner E, Olsen N, Fazio S . Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349(25):2407-15. DOI: 10.1056/NEJMoa035611. View

10.

Abu-Shakra M, Urowitz M, Gladman D, Gough J . Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995; 22(7):1259-64. View

11.

Roman M, Shanker B, Davis A, Lockshin M, Sammaritano L, Simantov R . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349(25):2399-406. DOI: 10.1056/NEJMoa035471. View

12.

. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23):2998-3007. DOI: 10.1001/jama.288.23.2998. View

13.

Liang M, Socher S, Roberts W, Esdaile J . Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988; 31(7):817-25. DOI: 10.1002/art.1780310701. View

14.

White H, Simes R, Anderson N, Hankey G, Watson J, Hunt D . Pravastatin therapy and the risk of stroke. N Engl J Med. 2000; 343(5):317-26. DOI: 10.1056/NEJM200008033430502. View

15.

Rahman P, Urowitz M, Gladman D, Bruce I, Genest Jr J . Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 1999; 26(11):2363-8. View

16.

Maron D, Fazio S, Linton M . Current perspectives on statins. Circulation. 2000; 101(2):207-13. DOI: 10.1161/01.cir.101.2.207. View

17.

Castelao A, Grinyo J, Castineiras M, Fiol C, Gilvernet S, Seron D . Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc. 1995; 27(4):2217-20. View

18.

Esdaile J, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R . Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44(10):2331-7. DOI: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i. View

19.

Manzi S, Meilahn E, Rairie J, Conte C, Medsger Jr T, DAgostino R . Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145(5):408-15. DOI: 10.1093/oxfordjournals.aje.a009122. View

20.

Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen J, Ballantyne C . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13):1556-65. DOI: 10.1001/jama.295.13.jpc60002. View